Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Transplantation

Rituximab induction for prevention of HLA-antibody rebound

Nature Reviews Nephrology volume 10, pages 682–683 (2014)Cite this article

Subjects

Desensitization therapy enables HLA-incompatible transplantation. However, desensitized patients have an increased risk of antibody-mediated rejection, and the presence of donor-specific antibodies (DSAs) is associated with poor outcomes. A new study has assessed the effect of rituximab induction on DSA production in kidney transplant recipients with high immunological risk.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Schold, J. D. et al. Comorbidity burden and perioperative complications for living kidney donors in the United States. Clin. J. Am. Soc. Nephrol. 8, 1773–1782 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Segev, D. L. et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 303, 959–966 (2010).

    Article  CAS  PubMed  Google Scholar 

  3. Montgomery, R. A. et al. Desensitization in HLA-incompatible kidney recipients and survival. N. Engl. J. Med. 365, 318–326 (2011).

    Article  CAS  PubMed  Google Scholar 

  4. Lefaucheur, C. et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am. J. Transplant. 8, 324–331 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. Lefaucheur, C. et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 21, 1398–1406 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jackson, A. M. et al. A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int. http://dx.doi.org/10.1038/ki.2014.261.

  7. Vo, A. A. et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359 242–251 (2008).

    Article  CAS  PubMed  Google Scholar 

  8. Jin, M. K. et al. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Transplant Proc. 44, 200–203 (2012).

    Article  CAS  PubMed  Google Scholar 

  9. Loupy, A. et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 89, 1403–1410 (2010).

    Article  CAS  PubMed  Google Scholar 

  10. Takagi, T., Ishida, H., Shirakawa, H., Shimizu, T. & Tanabe, K. Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation. Transpl. Immunol. 23 220–223 (2010).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Department of Transplant Surgery, University of Pittsburgh Medical Center, 3459 Fifth Avenue, Pittsburgh, 15213, PA, USA

    Puneet Sood & Sundaram Hariharan

Authors
  1. Puneet Sood
    View author publications

    Search author on:PubMed Google Scholar

  2. Sundaram Hariharan
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Sundaram Hariharan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sood, P., Hariharan, S. Rituximab induction for prevention of HLA-antibody rebound. Nat Rev Nephrol 10, 682–683 (2014). https://doi.org/10.1038/nrneph.2014.179

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneph.2014.179

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing